We develop treatments for serious, life-altering conditions that currently have no cure.
We combine innovative biotechnology with established pharmaceutical science – a link that’s widely considered to offer tremendous potential. This complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) means we can generate leading-edge prescription drugs of either origin.
Integral to our R&D programs is developing patient-friendly drug delivery systems. Most biopharmaceuticals have to be injected under the skin. But by making these injections easier and less painful, we aim at enhancing patient adherence to therapy.
At the Medical Design Excellence Awards (MDEA) ceremony, easypod®, our first electromechanical growth hormone injection device, received a gold medal for its innovative design and ease of use. We’ve now launched easypod® in over 40 countries where it’s had a positive response from both patients and healthcare professionals.
Find out more about our therapeutic areas and leading brands: